Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12


Alloanergization Method for Inducing Allospecific Hyporesponsiveness in PBMC Exposed to Allostimulation In Vitro in the Context of Costimulatory Molecule Blockade.

Barbon CM, Janec KJ, Kelner RH, Norton JE, Guinan EC.

Methods Mol Biol. 2019;1899:103-118. doi: 10.1007/978-1-4939-8938-6_8.


Alloanergization of human T cells results in expansion of alloantigen-specific CD8(+) CD28(-) suppressor cells.

Barbon CM, Davies JK, Voskertchian A, Kelner RH, Brennan LL, Nadler LM, Guinan EC.

Am J Transplant. 2014 Feb;14(2):305-18. doi: 10.1111/ajt.12575. Epub 2014 Jan 10.


Ex vivo alloanergization with belatacept: a strategy to selectively modulate alloresponses after transplantation.

Davies JK, Barbon CM, Voskertchian A, Nadler LM, Guinan EC.

Cell Transplant. 2012;21(9):2047-61. doi: 10.3727/096368912X637479. Epub 2012 Apr 10.


Bactericidal/permeability-increasing protein (rBPI21) and fluoroquinolone mitigate radiation-induced bone marrow aplasia and death.

Guinan EC, Barbon CM, Kalish LA, Parmar K, Kutok J, Mancuso CJ, Stoler-Barak L, Suter EE, Russell JD, Palmer CD, Gallington LC, Voskertchian A, Vergilio JA, Cole G, Zhu K, D'Andrea A, Soiffer R, Weiss JP, Levy O.

Sci Transl Med. 2011 Nov 23;3(110):110ra118. doi: 10.1126/scitranslmed.3003126.


Induction of alloantigen-specific anergy in human peripheral blood mononuclear cells by alloantigen stimulation with co-stimulatory signal blockade.

Davies JK, Barbon CM, Voskertchian AR, Nadler LM, Guinan EC.

J Vis Exp. 2011 Mar 14;(49). pii: 2673. doi: 10.3791/2673.


In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization.

Barbon CM, Baker L, Lajoie C, Ramstedt U, Hedley ML, Luby TM.

Vaccine. 2010 Nov 23;28(50):7852-64. doi: 10.1016/j.vaccine.2010.09.078. Epub 2010 Oct 28.


Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization.

Barbon CM, Yang M, Wands GD, Ramesh R, Slusher BS, Hedley ML, Luby TM.

Cell Immunol. 2010;262(2):150-61. doi: 10.1016/j.cellimm.2010.02.007. Epub 2010 Feb 12.


Pulmonary delivery of recombinant acid sphingomyelinase improves clearance of lysosomal sphingomyelin from the lungs of a murine model of Niemann-Pick disease.

Ziegler RJ, Brown C, Barbon CM, D'Angona AM, Schuchman EH, Andrews L, Thurberg BL, McPherson JM, Karey KP, Cheng SH.

Mol Genet Metab. 2009 May;97(1):35-42. doi: 10.1016/j.ymgme.2009.01.008. Epub 2009 Jan 25.


Correction of the Biochemical and Functional Deficits in Fabry Mice Following AAV8-mediated Hepatic Expression of α-galactosidase A.

Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D, Desnick RJ, Cheng SH.

Mol Ther. 2007 Mar;15(3):492-500. doi: 10.1038/ Epub 2016 Dec 8.


Correction of the biochemical and functional deficits in fabry mice following AAV8-mediated hepatic expression of alpha-galactosidase A.

Ziegler RJ, Cherry M, Barbon CM, Li C, Bercury SD, Armentano D, Desnick RJ, Cheng SH.

Mol Ther. 2007 Mar;15(3):492-500. Epub 2006 Dec 26.


AAV8-mediated hepatic expression of acid sphingomyelinase corrects the metabolic defect in the visceral organs of a mouse model of Niemann-Pick disease.

Barbon CM, Ziegler RJ, Li C, Armentano D, Cherry M, Desnick RJ, Schuchman EH, Cheng SH.

Mol Ther. 2005 Sep;12(3):431-40.


AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

Ziegler RJ, Lonning SM, Armentano D, Li C, Souza DW, Cherry M, Ford C, Barbon CM, Desnick RJ, Gao G, Wilson JM, Peluso R, Godwin S, Carter BJ, Gregory RJ, Wadsworth SC, Cheng SH.

Mol Ther. 2004 Feb;9(2):231-40.

Supplemental Content

Loading ...
Support Center